Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.67 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.58 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911847 | 0.87 | NPC1 (0.65) | S1PR1MKNK1MKNK2CYP11B2CYP19A1 | |
| SCHEMBL11342031 | 0.86 | KDM4E (0.70) | S1PR1MKNK1MKNK2CYP11B2CYP19A1 | |
| SCHEMBL30196133 | 0.86 | KDM4E (0.70) | S1PR1MKNK1MKNK2CYP11B2CYP19A1 | |
| Hydrochloric Acid SCHEMBL11336399 | 0.85 | KDM4E (0.68) | S1PR1MKNK1MKNK2CYP11B2CYP19A1 | |
| SCHEMBL1422699 | 0.84 | MAPK1 (0.80) | S1PR1MAPK1KDM4EHSD17B10NPC1 | |
| SCHEMBL1133223 | 0.82 | MKNK1 (0.56) | S1PR1MKNK1MKNK2CYP11B2CYP19A1 | |
| SCHEMBL519862 | 0.82 | HSD17B10 (0.65) | MKNK1MKNK2CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL10654961 | 0.82 | MKNK1 (0.59) | MKNK1MKNK2CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL10000581 | 0.81 | MKNK1 (0.49) | S1PR1MKNK1MKNK2CYP11B2CYP19A1 | |
| SCHEMBL13417017 | 0.81 | S1PR1 (1.00) | S1PR1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4227304-A2 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| EP-3736271-A1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| US-9040712-B2 | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions | NOVARTIS AG (CH) | 2015-05-26 | — | — | US | disclosed |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| EP-1567493-B1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PROD INC (US) | 2009-03-18 | — | — | EP | disclosed |
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7199243-B2 | Piperidine compounds useful as PPAR activators | PFIZER INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1567493-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | Pfizer Products Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040157885-A1 | PPAR activators | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
| WO-2004048334-A1 | PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS | PFIZER PRODUCTS INC. (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | S1PR1 397/4885MKNK1 3633/4885MKNK2 2436/4885 |
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | S1PR1 723/4885MKNK1 1629/4885MKNK2 1818/4885 |
| US-20040157885-A1 | PPAR activators | PPARA, PPARG, PPARD | S1PR1 723/4885MKNK1 1629/4885MKNK2 1818/4885 |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | S1PR1 2085/4885MKNK1 2126/4885MKNK2 1341/4885 |
| US-20140206661-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | S1PR1 2085/4885MKNK1 2126/4885MKNK2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.